| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain | 114 | 2023 | 1658 | 7.570 |
Why?
|
| Pain Measurement | 67 | 2019 | 953 | 6.590 |
Why?
|
| Fatigue | 61 | 2022 | 1239 | 6.420 |
Why?
|
| Severity of Illness Index | 83 | 2023 | 4320 | 4.540 |
Why?
|
| Patient Reported Outcome Measures | 35 | 2023 | 799 | 4.420 |
Why?
|
| Neoplasms | 162 | 2023 | 15193 | 4.320 |
Why?
|
| Quality of Life | 79 | 2023 | 4532 | 4.070 |
Why?
|
| Surveys and Questionnaires | 81 | 2023 | 5687 | 3.470 |
Why?
|
| Psychometrics | 33 | 2023 | 937 | 3.370 |
Why?
|
| Analgesics | 29 | 2015 | 390 | 3.080 |
Why?
|
| Pain Management | 34 | 2019 | 668 | 2.820 |
Why?
|
| Cost of Illness | 20 | 2016 | 498 | 2.470 |
Why?
|
| Multiple Myeloma | 19 | 2021 | 2138 | 2.130 |
Why?
|
| Health Status | 12 | 2017 | 590 | 1.960 |
Why?
|
| Peripheral Nervous System Diseases | 10 | 2019 | 393 | 1.860 |
Why?
|
| Activities of Daily Living | 15 | 2017 | 552 | 1.800 |
Why?
|
| Minocycline | 5 | 2021 | 182 | 1.780 |
Why?
|
| Sickness Impact Profile | 14 | 2017 | 139 | 1.780 |
Why?
|
| Reproducibility of Results | 59 | 2023 | 6009 | 1.640 |
Why?
|
| Middle Aged | 203 | 2022 | 86204 | 1.560 |
Why?
|
| Aged | 165 | 2023 | 70117 | 1.500 |
Why?
|
| Health Status Indicators | 10 | 2013 | 224 | 1.490 |
Why?
|
| Lung Neoplasms | 29 | 2023 | 11538 | 1.470 |
Why?
|
| Palliative Care | 24 | 2019 | 2037 | 1.410 |
Why?
|
| Sleep Wake Disorders | 13 | 2019 | 348 | 1.370 |
Why?
|
| Female | 231 | 2023 | 141928 | 1.340 |
Why?
|
| Humans | 350 | 2023 | 261506 | 1.340 |
Why?
|
| Male | 216 | 2023 | 123000 | 1.330 |
Why?
|
| Pain, Intractable | 17 | 2010 | 171 | 1.300 |
Why?
|
| Cancer Pain | 6 | 2023 | 312 | 1.290 |
Why?
|
| Adult | 163 | 2023 | 77950 | 1.230 |
Why?
|
| Clinical Trials as Topic | 20 | 2016 | 3719 | 1.190 |
Why?
|
| Health Surveys | 14 | 2019 | 402 | 1.190 |
Why?
|
| Symptom Assessment | 11 | 2021 | 267 | 1.190 |
Why?
|
| Bone Neoplasms | 13 | 2017 | 2576 | 1.160 |
Why?
|
| Antineoplastic Agents | 26 | 2020 | 14289 | 1.060 |
Why?
|
| Thoracotomy | 4 | 2022 | 220 | 1.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 16 | 2023 | 5319 | 0.970 |
Why?
|
| Aged, 80 and over | 73 | 2020 | 29902 | 0.960 |
Why?
|
| Head and Neck Neoplasms | 9 | 2019 | 3976 | 0.940 |
Why?
|
| Factor Analysis, Statistical | 16 | 2018 | 356 | 0.940 |
Why?
|
| Inflammation Mediators | 4 | 2014 | 423 | 0.940 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2016 | 600 | 0.930 |
Why?
|
| Self Report | 17 | 2017 | 756 | 0.880 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 6 | 2020 | 91 | 0.850 |
Why?
|
| Health Services Accessibility | 5 | 2011 | 761 | 0.850 |
Why?
|
| Translations | 6 | 2019 | 39 | 0.800 |
Why?
|
| Cross-Sectional Studies | 24 | 2023 | 4314 | 0.790 |
Why?
|
| Organoplatinum Compounds | 4 | 2016 | 702 | 0.770 |
Why?
|
| Practice Patterns, Physicians' | 13 | 2013 | 1303 | 0.750 |
Why?
|
| Medically Underserved Area | 4 | 2014 | 101 | 0.740 |
Why?
|
| Depression | 12 | 2019 | 1715 | 0.730 |
Why?
|
| Prevalence | 17 | 2017 | 3260 | 0.730 |
Why?
|
| Prospective Studies | 32 | 2023 | 12873 | 0.720 |
Why?
|
| Longitudinal Studies | 17 | 2023 | 1945 | 0.700 |
Why?
|
| Patient Satisfaction | 8 | 2015 | 915 | 0.700 |
Why?
|
| Thoracic Surgery, Video-Assisted | 3 | 2022 | 209 | 0.680 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2020 | 598 | 0.680 |
Why?
|
| Diphosphonates | 4 | 2015 | 262 | 0.680 |
Why?
|
| Bone Density Conservation Agents | 4 | 2014 | 198 | 0.680 |
Why?
|
| Narcotics | 3 | 2008 | 123 | 0.670 |
Why?
|
| Radiodermatitis | 1 | 2019 | 75 | 0.670 |
Why?
|
| Chronic Pain | 3 | 2023 | 238 | 0.670 |
Why?
|
| Attitude of Health Personnel | 9 | 2008 | 918 | 0.670 |
Why?
|
| Breast Neoplasms | 20 | 2021 | 15694 | 0.660 |
Why?
|
| Patient Participation | 4 | 2013 | 446 | 0.640 |
Why?
|
| Imidazoles | 5 | 2018 | 999 | 0.640 |
Why?
|
| Language | 11 | 2014 | 309 | 0.630 |
Why?
|
| Risk Assessment | 10 | 2014 | 6869 | 0.610 |
Why?
|
| Terminal Care | 5 | 2007 | 447 | 0.600 |
Why?
|
| Radiation Injuries | 5 | 2015 | 1411 | 0.600 |
Why?
|
| Sensitivity and Specificity | 13 | 2017 | 4971 | 0.600 |
Why?
|
| Pain, Postoperative | 5 | 2015 | 610 | 0.590 |
Why?
|
| Musculoskeletal Pain | 1 | 2017 | 21 | 0.580 |
Why?
|
| Work | 3 | 2015 | 24 | 0.580 |
Why?
|
| Terminology as Topic | 6 | 2015 | 414 | 0.560 |
Why?
|
| Paresthesia | 1 | 2016 | 33 | 0.560 |
Why?
|
| Genital Neoplasms, Female | 5 | 2021 | 735 | 0.550 |
Why?
|
| Healthcare Disparities | 2 | 2012 | 598 | 0.540 |
Why?
|
| Neoplasm Metastasis | 14 | 2018 | 5112 | 0.540 |
Why?
|
| Touch | 2 | 2016 | 71 | 0.540 |
Why?
|
| Androstadienes | 2 | 2013 | 165 | 0.540 |
Why?
|
| Survivors | 9 | 2021 | 1031 | 0.530 |
Why?
|
| Residence Characteristics | 5 | 2010 | 348 | 0.530 |
Why?
|
| Time Factors | 23 | 2017 | 12926 | 0.530 |
Why?
|
| Self-Assessment | 2 | 2013 | 96 | 0.520 |
Why?
|
| Cytokines | 8 | 2017 | 2809 | 0.520 |
Why?
|
| Colorectal Neoplasms | 8 | 2019 | 3578 | 0.520 |
Why?
|
| China | 13 | 2010 | 606 | 0.520 |
Why?
|
| Affect | 6 | 2013 | 288 | 0.520 |
Why?
|
| Research Design | 11 | 2020 | 1544 | 0.490 |
Why?
|
| Recovery of Function | 3 | 2016 | 703 | 0.490 |
Why?
|
| United States | 34 | 2020 | 15433 | 0.490 |
Why?
|
| Patient Discharge | 4 | 2023 | 661 | 0.490 |
Why?
|
| Double-Blind Method | 11 | 2021 | 2588 | 0.480 |
Why?
|
| Treatment Outcome | 44 | 2019 | 32848 | 0.480 |
Why?
|
| Stress, Psychological | 7 | 2014 | 1000 | 0.480 |
Why?
|
| Interleukin-6 | 5 | 2014 | 1038 | 0.470 |
Why?
|
| Hospitals, Public | 2 | 2011 | 64 | 0.470 |
Why?
|
| Inflammation | 6 | 2017 | 2522 | 0.470 |
Why?
|
| Morphine | 3 | 2008 | 308 | 0.460 |
Why?
|
| Socioeconomic Factors | 9 | 2019 | 1225 | 0.460 |
Why?
|
| Mesothelioma | 1 | 2018 | 544 | 0.450 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2014 | 132 | 0.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2017 | 6550 | 0.450 |
Why?
|
| Patient Outcome Assessment | 9 | 2023 | 245 | 0.450 |
Why?
|
| Adolescent | 41 | 2020 | 31252 | 0.450 |
Why?
|
| Antidepressive Agents | 2 | 2019 | 332 | 0.440 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2012 | 77 | 0.440 |
Why?
|
| Patients | 3 | 2010 | 245 | 0.440 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2012 | 142 | 0.430 |
Why?
|
| Data Collection | 8 | 2013 | 620 | 0.430 |
Why?
|
| Arthralgia | 1 | 2013 | 89 | 0.430 |
Why?
|
| Postoperative Period | 4 | 2021 | 665 | 0.430 |
Why?
|
| Health Care Costs | 2 | 2008 | 674 | 0.420 |
Why?
|
| Neuralgia | 4 | 2014 | 251 | 0.420 |
Why?
|
| Central Nervous System | 1 | 2014 | 436 | 0.410 |
Why?
|
| Young Adult | 27 | 2020 | 21445 | 0.410 |
Why?
|
| Translating | 5 | 2017 | 45 | 0.410 |
Why?
|
| Erythropoietin | 4 | 2008 | 205 | 0.410 |
Why?
|
| Chemoradiotherapy | 6 | 2019 | 1946 | 0.410 |
Why?
|
| Prednisone | 2 | 2013 | 984 | 0.400 |
Why?
|
| Opioid-Related Disorders | 2 | 2023 | 394 | 0.400 |
Why?
|
| Bortezomib | 4 | 2018 | 543 | 0.390 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2014 | 840 | 0.390 |
Why?
|
| Hematinics | 4 | 2012 | 109 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2020 | 2594 | 0.390 |
Why?
|
| Postoperative Complications | 5 | 2023 | 5542 | 0.390 |
Why?
|
| Anticonvulsants | 2 | 2014 | 431 | 0.390 |
Why?
|
| Spinal Fractures | 1 | 2012 | 132 | 0.380 |
Why?
|
| Patient Care Planning | 2 | 2012 | 297 | 0.380 |
Why?
|
| Radiotherapy | 5 | 2017 | 1824 | 0.380 |
Why?
|
| Mental Recall | 2 | 2017 | 171 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 3251 | 0.380 |
Why?
|
| Mucositis | 2 | 2008 | 148 | 0.370 |
Why?
|
| Comorbidity | 10 | 2015 | 2352 | 0.370 |
Why?
|
| Brain Neoplasms | 8 | 2020 | 4849 | 0.370 |
Why?
|
| Health Care Surveys | 5 | 2007 | 430 | 0.370 |
Why?
|
| Reminder Systems | 1 | 2011 | 83 | 0.370 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2010 | 11 | 0.370 |
Why?
|
| Data Interpretation, Statistical | 6 | 2019 | 482 | 0.360 |
Why?
|
| Combined Modality Therapy | 8 | 2019 | 8865 | 0.360 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2011 | 252 | 0.360 |
Why?
|
| Cancer Care Facilities | 6 | 2014 | 884 | 0.360 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2013 | 425 | 0.350 |
Why?
|
| Ambulatory Care | 6 | 2021 | 554 | 0.350 |
Why?
|
| Exercise | 1 | 2017 | 1183 | 0.350 |
Why?
|
| Cultural Characteristics | 3 | 2010 | 70 | 0.340 |
Why?
|
| Brain Mapping | 3 | 2008 | 644 | 0.340 |
Why?
|
| Drug Administration Schedule | 9 | 2017 | 3472 | 0.340 |
Why?
|
| United States Food and Drug Administration | 5 | 2017 | 332 | 0.330 |
Why?
|
| Models, Theoretical | 1 | 2013 | 785 | 0.330 |
Why?
|
| Triazoles | 1 | 2013 | 617 | 0.330 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2007 | 1039 | 0.320 |
Why?
|
| Cluster Analysis | 5 | 2015 | 1053 | 0.320 |
Why?
|
| Caregivers | 3 | 2012 | 677 | 0.320 |
Why?
|
| Nursing Audit | 1 | 2008 | 3 | 0.320 |
Why?
|
| Nitriles | 1 | 2013 | 906 | 0.320 |
Why?
|
| Denosumab | 5 | 2015 | 68 | 0.320 |
Why?
|
| Anemia, Hypochromic | 1 | 2007 | 16 | 0.310 |
Why?
|
| Analgesia | 5 | 1998 | 94 | 0.310 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 672 | 0.310 |
Why?
|
| Prostatic Neoplasms | 10 | 2017 | 5767 | 0.310 |
Why?
|
| Personality Inventory | 1 | 2008 | 178 | 0.300 |
Why?
|
| Taxoids | 3 | 2018 | 967 | 0.300 |
Why?
|
| Drug Evaluation | 1 | 2007 | 425 | 0.300 |
Why?
|
| Logistic Models | 7 | 2017 | 3441 | 0.300 |
Why?
|
| Risk Factors | 18 | 2017 | 17523 | 0.300 |
Why?
|
| Culture | 3 | 2012 | 100 | 0.300 |
Why?
|
| Tape Recording | 2 | 2006 | 14 | 0.300 |
Why?
|
| Ovarian Neoplasms | 2 | 2013 | 4638 | 0.300 |
Why?
|
| Analgesics, Opioid | 11 | 2023 | 1371 | 0.290 |
Why?
|
| Myeloproliferative Disorders | 1 | 2014 | 767 | 0.290 |
Why?
|
| Quality of Health Care | 2 | 2012 | 621 | 0.290 |
Why?
|
| Deglutition Disorders | 4 | 2019 | 447 | 0.290 |
Why?
|
| Nursing Care | 1 | 2006 | 13 | 0.290 |
Why?
|
| Karnofsky Performance Status | 6 | 2012 | 175 | 0.290 |
Why?
|
| Patient Education as Topic | 4 | 2008 | 748 | 0.290 |
Why?
|
| Korea | 7 | 2010 | 63 | 0.290 |
Why?
|
| Patient Care Management | 2 | 2004 | 94 | 0.280 |
Why?
|
| Fingers | 4 | 2014 | 120 | 0.280 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2013 | 901 | 0.270 |
Why?
|
| Telemedicine | 2 | 2015 | 471 | 0.270 |
Why?
|
| National Cancer Institute (U.S.) | 5 | 2020 | 211 | 0.270 |
Why?
|
| Pancreatitis | 1 | 2008 | 267 | 0.270 |
Why?
|
| Sex Factors | 5 | 2019 | 2139 | 0.270 |
Why?
|
| Transplantation, Autologous | 5 | 2015 | 1914 | 0.270 |
Why?
|
| Abdominal Pain | 1 | 2008 | 369 | 0.270 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2007 | 216 | 0.270 |
Why?
|
| Europe | 6 | 2017 | 649 | 0.260 |
Why?
|
| Urban Population | 1 | 2006 | 269 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 4549 | 0.260 |
Why?
|
| Regression Analysis | 4 | 2019 | 1546 | 0.260 |
Why?
|
| Quality Assurance, Health Care | 3 | 2003 | 585 | 0.250 |
Why?
|
| Osteoarthritis | 1 | 2005 | 94 | 0.250 |
Why?
|
| Social Values | 1 | 2004 | 62 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 15862 | 0.250 |
Why?
|
| Attitude to Health | 7 | 2008 | 465 | 0.250 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2023 | 356 | 0.250 |
Why?
|
| Public Opinion | 2 | 2004 | 83 | 0.240 |
Why?
|
| Medical Oncology | 7 | 2023 | 1423 | 0.240 |
Why?
|
| Urban Health Services | 1 | 2004 | 37 | 0.240 |
Why?
|
| Brazil | 3 | 2010 | 165 | 0.240 |
Why?
|
| Predictive Value of Tests | 9 | 2016 | 4892 | 0.240 |
Why?
|
| Philippines | 4 | 2010 | 39 | 0.240 |
Why?
|
| Isoxazoles | 1 | 2004 | 81 | 0.240 |
Why?
|
| Organizational Objectives | 1 | 2003 | 61 | 0.230 |
Why?
|
| Employment | 2 | 2015 | 129 | 0.230 |
Why?
|
| Neuroimmunomodulation | 1 | 2004 | 66 | 0.230 |
Why?
|
| Disease Progression | 9 | 2016 | 6682 | 0.230 |
Why?
|
| Magnetoencephalography | 2 | 1995 | 37 | 0.230 |
Why?
|
| Cohort Studies | 8 | 2015 | 9244 | 0.230 |
Why?
|
| Texas | 9 | 2020 | 6311 | 0.230 |
Why?
|
| Sleep | 3 | 2003 | 413 | 0.230 |
Why?
|
| Cognition Disorders | 6 | 2019 | 786 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2007 | 573 | 0.220 |
Why?
|
| Dyspnea | 4 | 2019 | 416 | 0.220 |
Why?
|
| Minority Groups | 2 | 2012 | 322 | 0.220 |
Why?
|
| Professional Competence | 1 | 2004 | 136 | 0.220 |
Why?
|
| Thyroid Neoplasms | 2 | 2015 | 1866 | 0.220 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 4298 | 0.210 |
Why?
|
| Fabry Disease | 1 | 2002 | 15 | 0.210 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 13658 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2019 | 521 | 0.210 |
Why?
|
| Health Services Needs and Demand | 2 | 2002 | 244 | 0.210 |
Why?
|
| Anemia | 4 | 2012 | 689 | 0.200 |
Why?
|
| Brain | 4 | 2008 | 4113 | 0.200 |
Why?
|
| Analysis of Variance | 7 | 2010 | 2307 | 0.200 |
Why?
|
| Observer Variation | 1 | 2003 | 671 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2006 | 1209 | 0.200 |
Why?
|
| Aftercare | 1 | 2023 | 259 | 0.200 |
Why?
|
| Guidelines as Topic | 3 | 2010 | 383 | 0.200 |
Why?
|
| Transplantation Conditioning | 3 | 2017 | 2238 | 0.190 |
Why?
|
| Peru | 3 | 2015 | 52 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 1 | 2003 | 289 | 0.190 |
Why?
|
| Models, Animal | 1 | 2003 | 664 | 0.190 |
Why?
|
| Behavior, Animal | 2 | 2003 | 709 | 0.190 |
Why?
|
| Endpoint Determination | 3 | 2010 | 176 | 0.190 |
Why?
|
| Exanthema | 1 | 2022 | 211 | 0.180 |
Why?
|
| Cold Temperature | 4 | 2014 | 121 | 0.180 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 860 | 0.180 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 14889 | 0.180 |
Why?
|
| Fluorouracil | 3 | 2009 | 1944 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2019 | 604 | 0.170 |
Why?
|
| Depressive Disorder | 1 | 2003 | 557 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 10035 | 0.170 |
Why?
|
| Area Under Curve | 2 | 2019 | 700 | 0.170 |
Why?
|
| Retrospective Studies | 15 | 2019 | 37905 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 64 | 0.160 |
Why?
|
| Biomarkers | 4 | 2021 | 5047 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2021 | 202 | 0.160 |
Why?
|
| Diarrhea | 3 | 2022 | 686 | 0.160 |
Why?
|
| Physician-Patient Relations | 3 | 2019 | 792 | 0.160 |
Why?
|
| Physicians | 3 | 2013 | 882 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2018 | 49 | 0.160 |
Why?
|
| Critical Pathways | 2 | 2017 | 149 | 0.160 |
Why?
|
| Rectal Neoplasms | 2 | 2009 | 1202 | 0.160 |
Why?
|
| Consumer Health Information | 1 | 2018 | 52 | 0.160 |
Why?
|
| Cuba | 2 | 2008 | 10 | 0.160 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2017 | 1105 | 0.160 |
Why?
|
| Argentina | 2 | 2008 | 72 | 0.160 |
Why?
|
| Outpatients | 2 | 2012 | 462 | 0.160 |
Why?
|
| Bridged-Ring Compounds | 1 | 2018 | 183 | 0.160 |
Why?
|
| Japan | 7 | 2020 | 227 | 0.160 |
Why?
|
| Latin America | 2 | 2008 | 115 | 0.150 |
Why?
|
| Chronic Disease | 6 | 2011 | 1819 | 0.150 |
Why?
|
| Iran | 1 | 2017 | 68 | 0.150 |
Why?
|
| Central Venous Catheters | 1 | 2018 | 98 | 0.150 |
Why?
|
| Internet | 2 | 2019 | 706 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 500 | 0.150 |
Why?
|
| Turkey | 1 | 2017 | 57 | 0.150 |
Why?
|
| Mexico | 2 | 2008 | 259 | 0.150 |
Why?
|
| France | 5 | 2010 | 108 | 0.150 |
Why?
|
| Greece | 3 | 2008 | 22 | 0.150 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 61 | 0.150 |
Why?
|
| Indonesia | 1 | 2016 | 17 | 0.150 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 48 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2021 | 451 | 0.150 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2016 | 22 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2992 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 2403 | 0.140 |
Why?
|
| Postoperative Care | 3 | 2015 | 739 | 0.140 |
Why?
|
| Constipation | 3 | 2015 | 177 | 0.140 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 10001 | 0.140 |
Why?
|
| Anxiety | 4 | 2022 | 1179 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2009 | 1299 | 0.140 |
Why?
|
| RANK Ligand | 2 | 2014 | 119 | 0.140 |
Why?
|
| Abiraterone Acetate | 2 | 2013 | 70 | 0.140 |
Why?
|
| Public Health Administration | 1 | 1996 | 13 | 0.140 |
Why?
|
| Medical Informatics | 1 | 2018 | 198 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 1870 | 0.140 |
Why?
|
| Device Removal | 1 | 2018 | 337 | 0.140 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 301 | 0.140 |
Why?
|
| Pyridazines | 1 | 2018 | 293 | 0.140 |
Why?
|
| ROC Curve | 1 | 2019 | 1183 | 0.140 |
Why?
|
| Aluminum Silicates | 1 | 2015 | 15 | 0.140 |
Why?
|
| Drug Prescriptions | 2 | 1997 | 289 | 0.130 |
Why?
|
| Interleukin-10 | 3 | 2014 | 478 | 0.130 |
Why?
|
| Antidiarrheals | 1 | 2015 | 37 | 0.130 |
Why?
|
| Cooperative Behavior | 2 | 2010 | 313 | 0.130 |
Why?
|
| Biofeedback, Psychology | 4 | 1985 | 49 | 0.130 |
Why?
|
| Proton Therapy | 2 | 2016 | 1577 | 0.130 |
Why?
|
| Cachexia | 1 | 2017 | 161 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2014 | 2231 | 0.130 |
Why?
|
| Germany | 3 | 2014 | 111 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 2018 | 354 | 0.130 |
Why?
|
| Electromagnetic Fields | 2 | 1995 | 50 | 0.130 |
Why?
|
| Tonsillar Neoplasms | 1 | 2015 | 80 | 0.130 |
Why?
|
| Mood Disorders | 1 | 2016 | 163 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2004 | 1823 | 0.130 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2014 | 16 | 0.130 |
Why?
|
| Vinca Alkaloids | 1 | 2014 | 9 | 0.130 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2014 | 12 | 0.130 |
Why?
|
| Cyclohexanols | 1 | 2014 | 15 | 0.130 |
Why?
|
| Dasatinib | 1 | 2018 | 862 | 0.130 |
Why?
|
| Carbamazepine | 1 | 2014 | 49 | 0.130 |
Why?
|
| Radiation Oncology | 1 | 2000 | 529 | 0.130 |
Why?
|
| Amitriptyline | 1 | 2014 | 38 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2021 | 650 | 0.130 |
Why?
|
| Evoked Potentials | 3 | 1995 | 190 | 0.130 |
Why?
|
| Pneumonectomy | 2 | 2022 | 831 | 0.120 |
Why?
|
| Forecasting | 2 | 2005 | 694 | 0.120 |
Why?
|
| Xerostomia | 3 | 2015 | 190 | 0.120 |
Why?
|
| Epothilones | 1 | 2014 | 54 | 0.120 |
Why?
|
| Thalidomide | 2 | 2016 | 569 | 0.120 |
Why?
|
| Databases, Factual | 3 | 2016 | 2218 | 0.120 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2014 | 52 | 0.120 |
Why?
|
| Protective Agents | 1 | 2014 | 51 | 0.120 |
Why?
|
| Pediatrics | 1 | 2003 | 1141 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 406 | 0.120 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2018 | 505 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 419 | 0.120 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.120 |
Why?
|
| Head | 1 | 1995 | 249 | 0.120 |
Why?
|
| Thiophenes | 1 | 2014 | 148 | 0.120 |
Why?
|
| Carcinoma, Medullary | 1 | 2015 | 248 | 0.120 |
Why?
|
| Amyloidosis | 1 | 2015 | 176 | 0.110 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 300 | 0.110 |
Why?
|
| Hypesthesia | 1 | 2013 | 22 | 0.110 |
Why?
|
| Methylphenidate | 1 | 2014 | 103 | 0.110 |
Why?
|
| Australia | 1 | 2013 | 225 | 0.110 |
Why?
|
| Leukemia | 1 | 2002 | 1635 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 980 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 3 | 1999 | 418 | 0.110 |
Why?
|
| Prognosis | 8 | 2016 | 21713 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2014 | 1538 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2014 | 362 | 0.110 |
Why?
|
| Kyphoplasty | 1 | 2012 | 9 | 0.110 |
Why?
|
| Leukocyte Count | 1 | 2014 | 684 | 0.110 |
Why?
|
| Canada | 1 | 2013 | 429 | 0.110 |
Why?
|
| Photons | 1 | 2016 | 507 | 0.110 |
Why?
|
| Cross-Cultural Comparison | 2 | 1994 | 87 | 0.110 |
Why?
|
| Vertebroplasty | 1 | 2012 | 24 | 0.110 |
Why?
|
| Marriage | 1 | 1992 | 45 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2011 | 2316 | 0.100 |
Why?
|
| Nomograms | 1 | 2014 | 313 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2013 | 4988 | 0.100 |
Why?
|
| Alpha Rhythm | 1 | 1991 | 14 | 0.100 |
Why?
|
| Incidence | 3 | 2013 | 5673 | 0.100 |
Why?
|
| Fractures, Compression | 1 | 2012 | 42 | 0.100 |
Why?
|
| Taiwan | 4 | 2008 | 93 | 0.100 |
Why?
|
| Rituximab | 1 | 2017 | 1528 | 0.100 |
Why?
|
| Pyrazines | 1 | 2014 | 495 | 0.100 |
Why?
|
| Psychological Tests | 8 | 2008 | 131 | 0.100 |
Why?
|
| American Cancer Society | 1 | 2011 | 31 | 0.100 |
Why?
|
| Models, Statistical | 2 | 2018 | 1171 | 0.100 |
Why?
|
| Feeding and Eating Disorders | 1 | 2012 | 97 | 0.100 |
Why?
|
| Pharyngitis | 1 | 2011 | 41 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 1287 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 2 | 2020 | 5061 | 0.100 |
Why?
|
| Electronic Mail | 1 | 2011 | 53 | 0.100 |
Why?
|
| Vocabulary | 1 | 1990 | 23 | 0.100 |
Why?
|
| Russia | 4 | 2010 | 54 | 0.090 |
Why?
|
| Spinal Cord Compression | 1 | 2012 | 151 | 0.090 |
Why?
|
| Algorithms | 7 | 2020 | 3890 | 0.090 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 669 | 0.090 |
Why?
|
| Radiosurgery | 2 | 2012 | 1330 | 0.090 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.090 |
Why?
|
| Behavior Therapy | 3 | 1986 | 298 | 0.090 |
Why?
|
| Metformin | 1 | 2014 | 378 | 0.090 |
Why?
|
| Telephone | 1 | 2011 | 163 | 0.090 |
Why?
|
| Research | 3 | 2006 | 415 | 0.090 |
Why?
|
| Vietnam | 2 | 2006 | 56 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 586 | 0.090 |
Why?
|
| Proof of Concept Study | 2 | 2019 | 53 | 0.090 |
Why?
|
| Cognition | 3 | 2013 | 968 | 0.090 |
Why?
|
| Adaptation, Psychological | 2 | 2012 | 764 | 0.090 |
Why?
|
| Developing Countries | 2 | 2006 | 315 | 0.090 |
Why?
|
| Perioperative Period | 2 | 2021 | 155 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.080 |
Why?
|
| Health Services Research | 1 | 2010 | 233 | 0.080 |
Why?
|
| Hepatectomy | 1 | 2015 | 1011 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 1910 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 6207 | 0.080 |
Why?
|
| Rats, Inbred Lew | 1 | 2008 | 113 | 0.080 |
Why?
|
| Afferent Pathways | 1 | 2008 | 64 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3203 | 0.080 |
Why?
|
| Printing | 1 | 2008 | 7 | 0.080 |
Why?
|
| Italy | 2 | 2001 | 236 | 0.080 |
Why?
|
| Propensity Score | 1 | 2011 | 750 | 0.080 |
Why?
|
| Hospitals, Private | 1 | 2008 | 23 | 0.080 |
Why?
|
| Attention | 1 | 1990 | 281 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2019 | 1987 | 0.080 |
Why?
|
| Taste Disorders | 1 | 2007 | 17 | 0.080 |
Why?
|
| Mastication | 1 | 2007 | 19 | 0.080 |
Why?
|
| Product Labeling | 1 | 2007 | 13 | 0.080 |
Why?
|
| Nausea | 4 | 2015 | 525 | 0.080 |
Why?
|
| Oral Ulcer | 1 | 2007 | 15 | 0.080 |
Why?
|
| Darbepoetin alfa | 1 | 2007 | 26 | 0.080 |
Why?
|
| Videotape Recording | 1 | 2008 | 74 | 0.080 |
Why?
|
| Flecainide | 1 | 2007 | 27 | 0.080 |
Why?
|
| Affective Symptoms | 4 | 1984 | 102 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 2104 | 0.080 |
Why?
|
| Patient Compliance | 3 | 2008 | 667 | 0.080 |
Why?
|
| Age Factors | 5 | 2019 | 5377 | 0.080 |
Why?
|
| International Cooperation | 1 | 2009 | 323 | 0.080 |
Why?
|
| Voice Disorders | 1 | 2007 | 39 | 0.080 |
Why?
|
| Oxycodone | 1 | 2007 | 29 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2005 | 1544 | 0.080 |
Why?
|
| Acute Disease | 4 | 2013 | 2422 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 660 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.070 |
Why?
|
| Electromyography | 5 | 1984 | 226 | 0.070 |
Why?
|
| International Agencies | 1 | 2006 | 107 | 0.070 |
Why?
|
| Genotype | 1 | 2014 | 4109 | 0.070 |
Why?
|
| Risk | 1 | 2010 | 1972 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2014 | 6100 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 4938 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3518 | 0.070 |
Why?
|
| Social Class | 2 | 2014 | 310 | 0.070 |
Why?
|
| Patient Selection | 3 | 2010 | 2055 | 0.070 |
Why?
|
| Emotions | 3 | 2003 | 562 | 0.070 |
Why?
|
| Self Concept | 2 | 2002 | 211 | 0.070 |
Why?
|
| Raynaud Disease | 1 | 1985 | 10 | 0.070 |
Why?
|
| Skin Temperature | 3 | 2014 | 32 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2006 | 495 | 0.060 |
Why?
|
| Drug Utilization | 2 | 1998 | 179 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 1085 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 698 | 0.060 |
Why?
|
| Drug Administration Routes | 1 | 2004 | 60 | 0.060 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2004 | 101 | 0.060 |
Why?
|
| Endorphins | 1 | 1984 | 21 | 0.060 |
Why?
|
| Anesthesia, Epidural | 1 | 2004 | 31 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 200 | 0.060 |
Why?
|
| Myelography | 1 | 1984 | 16 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 2390 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2005 | 477 | 0.060 |
Why?
|
| Poverty | 2 | 2015 | 471 | 0.060 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2004 | 68 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2012 | 2203 | 0.060 |
Why?
|
| Sensory Thresholds | 2 | 2014 | 68 | 0.060 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 58 | 0.060 |
Why?
|
| Recurrence | 2 | 2011 | 4758 | 0.060 |
Why?
|
| Stuttering | 1 | 1983 | 5 | 0.060 |
Why?
|
| Interinstitutional Relations | 1 | 2003 | 37 | 0.060 |
Why?
|
| Arthritis | 1 | 2004 | 139 | 0.060 |
Why?
|
| Symptom Flare Up | 1 | 2023 | 22 | 0.060 |
Why?
|
| Indians, North American | 1 | 1983 | 87 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4757 | 0.060 |
Why?
|
| Length of Stay | 2 | 2023 | 1900 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2014 | 1996 | 0.050 |
Why?
|
| Nurses | 1 | 1983 | 80 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 435 | 0.050 |
Why?
|
| Vomiting | 2 | 2015 | 354 | 0.050 |
Why?
|
| Program Development | 1 | 2003 | 261 | 0.050 |
Why?
|
| Spinal Neoplasms | 1 | 2007 | 631 | 0.050 |
Why?
|
| Nerve Block | 1 | 2004 | 176 | 0.050 |
Why?
|
| Sleep Stages | 2 | 2014 | 78 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 2527 | 0.050 |
Why?
|
| Sensation | 3 | 2012 | 71 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 1648 | 0.050 |
Why?
|
| Anorexia | 2 | 2014 | 143 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2002 | 257 | 0.050 |
Why?
|
| Blood Transfusion | 3 | 2012 | 583 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 2638 | 0.050 |
Why?
|
| Animals | 5 | 2014 | 59536 | 0.050 |
Why?
|
| Hospitals, General | 1 | 2001 | 27 | 0.050 |
Why?
|
| Hospitals, Veterans | 1 | 2003 | 397 | 0.050 |
Why?
|
| Relaxation | 2 | 1986 | 7 | 0.050 |
Why?
|
| Fractures, Spontaneous | 2 | 2015 | 84 | 0.050 |
Why?
|
| Global Health | 2 | 1998 | 657 | 0.050 |
Why?
|
| Delayed-Action Preparations | 2 | 2014 | 208 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2002 | 756 | 0.050 |
Why?
|
| Jordan | 1 | 2019 | 24 | 0.050 |
Why?
|
| Rats | 2 | 2008 | 6086 | 0.050 |
Why?
|
| Medical Staff, Hospital | 1 | 2001 | 118 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 38 | 0.050 |
Why?
|
| Arabs | 1 | 2019 | 38 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2003 | 605 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 406 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 4557 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 5437 | 0.040 |
Why?
|
| Multiple Sclerosis | 3 | 1972 | 349 | 0.040 |
Why?
|
| Registries | 1 | 2007 | 2170 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2019 | 57 | 0.040 |
Why?
|
| Urodynamics | 1 | 1979 | 57 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2008 | 7702 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 708 | 0.040 |
Why?
|
| Urination Disorders | 1 | 1979 | 61 | 0.040 |
Why?
|
| Electroshock | 2 | 1995 | 46 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2018 | 75 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2013 | 497 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2001 | 290 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2018 | 54 | 0.040 |
Why?
|
| Walking | 1 | 2001 | 277 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3890 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2023 | 710 | 0.040 |
Why?
|
| India | 1 | 1999 | 301 | 0.040 |
Why?
|
| Organizations | 1 | 1998 | 23 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 3168 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 849 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 134 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2004 | 1529 | 0.040 |
Why?
|
| Aging | 1 | 2006 | 1582 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 10331 | 0.040 |
Why?
|
| Hemiplegia | 1 | 1977 | 47 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 447 | 0.040 |
Why?
|
| Time | 1 | 2017 | 178 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 1997 | 74 | 0.040 |
Why?
|
| Neurologic Examination | 2 | 2014 | 245 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2000 | 461 | 0.040 |
Why?
|
| Disease Management | 2 | 2015 | 1052 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2015 | 9180 | 0.030 |
Why?
|
| Counseling | 2 | 2010 | 381 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2015 | 22 | 0.030 |
Why?
|
| Child | 7 | 2008 | 29154 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 978 | 0.030 |
Why?
|
| Pain Clinics | 2 | 2007 | 17 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 5539 | 0.030 |
Why?
|
| Electroencephalography | 6 | 1991 | 898 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2015 | 69 | 0.030 |
Why?
|
| MMPI | 3 | 1971 | 22 | 0.030 |
Why?
|
| Functional Laterality | 2 | 1995 | 316 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 151 | 0.030 |
Why?
|
| Florida | 1 | 2014 | 113 | 0.030 |
Why?
|
| Movement Disorders | 1 | 1977 | 232 | 0.030 |
Why?
|
| Sensorimotor Cortex | 1 | 2014 | 22 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2292 | 0.030 |
Why?
|
| Epidemiology | 1 | 1994 | 12 | 0.030 |
Why?
|
| Heart Failure | 1 | 2008 | 2516 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2014 | 106 | 0.030 |
Why?
|
| Standard of Care | 1 | 2015 | 243 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1559 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 334 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2014 | 209 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2001 | 3842 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2014 | 281 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2015 | 167 | 0.030 |
Why?
|
| Professional Practice | 1 | 2013 | 82 | 0.030 |
Why?
|
| Speech Disorders | 2 | 1973 | 91 | 0.030 |
Why?
|
| Data Mining | 1 | 2013 | 88 | 0.030 |
Why?
|
| Unemployment | 1 | 2013 | 31 | 0.030 |
Why?
|
| Lip | 1 | 1973 | 33 | 0.030 |
Why?
|
| Stomatitis | 1 | 2014 | 183 | 0.030 |
Why?
|
| Torticollis | 1 | 1973 | 72 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 1763 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 437 | 0.030 |
Why?
|
| Castration | 1 | 2012 | 122 | 0.030 |
Why?
|
| Wisconsin | 2 | 1988 | 27 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 1290 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 968 | 0.030 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 1970 | 101 | 0.030 |
Why?
|
| Checklist | 1 | 2013 | 122 | 0.030 |
Why?
|
| Executive Function | 1 | 2013 | 160 | 0.030 |
Why?
|
| Acetaminophen | 1 | 2013 | 116 | 0.030 |
Why?
|
| Mass Screening | 2 | 2013 | 1509 | 0.030 |
Why?
|
| Parkinson Disease | 2 | 1984 | 708 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 460 | 0.030 |
Why?
|
| Body Temperature Regulation | 1 | 1972 | 38 | 0.030 |
Why?
|
| Neurologic Manifestations | 1 | 1971 | 10 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2014 | 238 | 0.030 |
Why?
|
| Remission Induction | 2 | 2009 | 3569 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 663 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 225 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 1996 | 1178 | 0.030 |
Why?
|
| Botulism | 1 | 1971 | 8 | 0.030 |
Why?
|
| Cortical Synchronization | 1 | 1991 | 13 | 0.030 |
Why?
|
| Hand | 2 | 1991 | 170 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 2013 | 229 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2012 | 102 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1991 | 60 | 0.030 |
Why?
|
| Survival | 1 | 2011 | 177 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 1991 | 112 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 196 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2016 | 1014 | 0.020 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1991 | 19 | 0.020 |
Why?
|
| Craniocerebral Trauma | 2 | 1972 | 130 | 0.020 |
Why?
|
| Liver | 1 | 2021 | 2961 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 1995 | 621 | 0.020 |
Why?
|
| Pain Perception | 1 | 2010 | 13 | 0.020 |
Why?
|
| Morocco | 1 | 2010 | 5 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2016 | 1450 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 360 | 0.020 |
Why?
|
| Environmental Health | 1 | 1970 | 21 | 0.020 |
Why?
|
| Social Support | 1 | 2013 | 560 | 0.020 |
Why?
|
| Memory | 1 | 2013 | 429 | 0.020 |
Why?
|
| Learning | 1 | 2013 | 403 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1991 | 426 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2010 | 200 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 1970 | 111 | 0.020 |
Why?
|
| Probability Theory | 1 | 2008 | 6 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 66 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2803 | 0.020 |
Why?
|
| Physical Examination | 1 | 2010 | 299 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 1960 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 726 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 703 | 0.020 |
Why?
|
| Societies, Medical | 1 | 1995 | 1335 | 0.020 |
Why?
|
| Stem Cells | 1 | 2015 | 1213 | 0.020 |
Why?
|
| Thiotepa | 1 | 2008 | 118 | 0.020 |
Why?
|
| Epinephrine | 2 | 1972 | 255 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 2008 | 73 | 0.020 |
Why?
|
| Capecitabine | 1 | 2009 | 388 | 0.020 |
Why?
|
| Epidural Space | 1 | 2007 | 42 | 0.020 |
Why?
|
| Family Health | 1 | 1988 | 325 | 0.020 |
Why?
|
| Visual Acuity | 1 | 1972 | 873 | 0.020 |
Why?
|
| Topotecan | 1 | 2008 | 239 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2010 | 443 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1503 | 0.020 |
Why?
|
| Epilepsy, Absence | 1 | 1967 | 35 | 0.020 |
Why?
|
| Decision Trees | 1 | 2007 | 178 | 0.020 |
Why?
|
| Carnitine | 1 | 2007 | 94 | 0.020 |
Why?
|
| Arousal | 1 | 1967 | 120 | 0.020 |
Why?
|
| Behavior | 2 | 1983 | 103 | 0.020 |
Why?
|
| Focus Groups | 1 | 2007 | 256 | 0.020 |
Why?
|
| Population | 1 | 2006 | 27 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 2432 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 169 | 0.020 |
Why?
|
| Myasthenia Gravis | 1 | 1967 | 99 | 0.020 |
Why?
|
| Chest Pain | 1 | 2007 | 155 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2007 | 249 | 0.020 |
Why?
|
| Total Quality Management | 1 | 1995 | 34 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 415 | 0.020 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 1985 | 2 | 0.020 |
Why?
|
| Collagen Diseases | 1 | 1985 | 6 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 1985 | 42 | 0.020 |
Why?
|
| Survival Rate | 2 | 2009 | 12221 | 0.020 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1985 | 29 | 0.020 |
Why?
|
| Melphalan | 1 | 2008 | 834 | 0.020 |
Why?
|
| Models, Psychological | 1 | 1986 | 170 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 1985 | 77 | 0.020 |
Why?
|
| Psychosocial Deprivation | 1 | 1994 | 8 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 3981 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2006 | 250 | 0.020 |
Why?
|
| Body Temperature | 1 | 1985 | 158 | 0.020 |
Why?
|
| Chlorpromazine | 1 | 1964 | 17 | 0.020 |
Why?
|
| Celiac Plexus | 1 | 2004 | 13 | 0.020 |
Why?
|
| Computers | 1 | 1984 | 141 | 0.020 |
Why?
|
| beta-Endorphin | 1 | 1984 | 42 | 0.020 |
Why?
|
| Intervertebral Disc | 1 | 1984 | 21 | 0.020 |
Why?
|
| Retreatment | 1 | 2005 | 452 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2004 | 257 | 0.010 |
Why?
|
| Epilepsy | 2 | 1969 | 883 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 1391 | 0.010 |
Why?
|
| Mental Health | 1 | 2007 | 415 | 0.010 |
Why?
|
| Peripheral Nerve Injuries | 1 | 1994 | 60 | 0.010 |
Why?
|
| Sick Role | 1 | 1983 | 64 | 0.010 |
Why?
|
| Busulfan | 1 | 2008 | 764 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 1985 | 134 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1985 | 410 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1964 | 156 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 156 | 0.010 |
Why?
|
| Injections | 1 | 1964 | 285 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 6942 | 0.010 |
Why?
|
| Prejudice | 1 | 1983 | 57 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2009 | 1353 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 558 | 0.010 |
Why?
|
| Norway | 1 | 2002 | 30 | 0.010 |
Why?
|
| Spinal Diseases | 1 | 1984 | 125 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5178 | 0.010 |
Why?
|
| Attitude | 1 | 1984 | 159 | 0.010 |
Why?
|
| Analgesia, Epidural | 1 | 2004 | 102 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 4367 | 0.010 |
Why?
|
| Oncology Service, Hospital | 1 | 2003 | 48 | 0.010 |
Why?
|
| Epoetin Alfa | 1 | 2002 | 27 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1985 | 223 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 461 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 253 | 0.010 |
Why?
|
| Feedback | 2 | 1973 | 198 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 589 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 2843 | 0.010 |
Why?
|
| Motion Pictures | 2 | 1973 | 23 | 0.010 |
Why?
|
| Documentation | 1 | 2004 | 207 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 519 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 7222 | 0.010 |
Why?
|
| Probability | 1 | 1982 | 866 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 2086 | 0.010 |
Why?
|
| History, 20th Century | 1 | 1983 | 574 | 0.010 |
Why?
|
| Family | 1 | 1994 | 736 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2011 | 1797 | 0.010 |
Why?
|
| Body Weight | 1 | 1994 | 1293 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1984 | 795 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 1547 | 0.010 |
Why?
|
| Urethra | 1 | 1979 | 144 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 1979 | 117 | 0.010 |
Why?
|
| Victoria | 1 | 1998 | 17 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 1979 | 149 | 0.010 |
Why?
|
| HIV Infections | 1 | 2010 | 2134 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1977 | 12 | 0.010 |
Why?
|
| Colonic Neoplasms | 2 | 1983 | 1390 | 0.010 |
Why?
|
| Health Benefit Plans, Employee | 1 | 1997 | 5 | 0.010 |
Why?
|
| Capitation Fee | 1 | 1997 | 4 | 0.010 |
Why?
|
| Software | 1 | 1984 | 1321 | 0.010 |
Why?
|
| Case Management | 1 | 1997 | 35 | 0.010 |
Why?
|
| Computer Communication Networks | 1 | 1997 | 44 | 0.010 |
Why?
|
| Motor Skills | 1 | 1977 | 107 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 3001 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 2927 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2004 | 3005 | 0.010 |
Why?
|
| Methods | 2 | 1973 | 189 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 1998 | 298 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 4975 | 0.010 |
Why?
|
| Drug Costs | 1 | 1997 | 144 | 0.010 |
Why?
|
| Intelligence Tests | 2 | 1971 | 88 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 362 | 0.010 |
Why?
|
| Problem Solving | 2 | 1971 | 85 | 0.010 |
Why?
|
| Intelligence | 2 | 1971 | 126 | 0.010 |
Why?
|
| Oscillometry | 1 | 1973 | 26 | 0.010 |
Why?
|
| Avoidance Learning | 1 | 1973 | 94 | 0.010 |
Why?
|
| Voice | 2 | 1969 | 23 | 0.010 |
Why?
|
| Electrodes, Implanted | 1 | 1973 | 183 | 0.010 |
Why?
|
| Unconsciousness | 1 | 1972 | 21 | 0.010 |
Why?
|
| Aphasia | 1 | 1972 | 21 | 0.010 |
Why?
|
| Hematoma, Subdural | 1 | 1972 | 28 | 0.010 |
Why?
|
| Posture | 1 | 1973 | 215 | 0.010 |
Why?
|
| Skull Fractures | 1 | 1972 | 46 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 7591 | 0.010 |
Why?
|
| Psychoneuroimmunology | 1 | 1991 | 22 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 7551 | 0.010 |
Why?
|
| Neuropsychology | 1 | 1991 | 33 | 0.010 |
Why?
|
| Tremor | 1 | 1972 | 128 | 0.010 |
Why?
|
| Temperature | 1 | 1972 | 506 | 0.010 |
Why?
|
| Noise | 1 | 1970 | 29 | 0.010 |
Why?
|
| Botulinum Toxins | 1 | 1971 | 129 | 0.010 |
Why?
|
| Education, Medical | 1 | 1993 | 331 | 0.010 |
Why?
|
| Kinetics | 1 | 1972 | 2049 | 0.010 |
Why?
|
| Heart Rate | 1 | 1972 | 737 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 1991 | 310 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1972 | 492 | 0.010 |
Why?
|
| Sensory Deprivation | 1 | 1967 | 35 | 0.000 |
Why?
|
| Mental Processes | 1 | 1967 | 53 | 0.000 |
Why?
|
| Huntington Disease | 1 | 1968 | 135 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1972 | 1467 | 0.000 |
Why?
|
| Muscle Relaxation | 1 | 1984 | 19 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1990 | 16273 | 0.000 |
Why?
|
| Hypochondriasis | 1 | 1970 | 2 | 0.000 |
Why?
|
| Brain Damage, Chronic | 1 | 1970 | 37 | 0.000 |
Why?
|
| Reinforcement Schedule | 1 | 1969 | 26 | 0.000 |
Why?
|
| Epilepsy, Post-Traumatic | 1 | 1969 | 12 | 0.000 |
Why?
|
| Educational Status | 1 | 1970 | 397 | 0.000 |
Why?
|
| Wakefulness | 1 | 1969 | 150 | 0.000 |
Why?
|
| Ophthalmoplegia | 1 | 1968 | 79 | 0.000 |
Why?
|
| Muscular Diseases | 1 | 1968 | 161 | 0.000 |
Why?
|
| Schizophrenia | 1 | 1970 | 369 | 0.000 |
Why?
|
| Motor Activity | 1 | 1970 | 693 | 0.000 |
Why?
|
| Perception | 1 | 1968 | 350 | 0.000 |
Why?
|
| Pedigree | 1 | 1968 | 1890 | 0.000 |
Why?
|
| Intellectual Disability | 1 | 1968 | 1032 | 0.000 |
Why?
|